Kornimate/medical-research-clean huggingface dataset:
glowtest covid-19 antigen home test kit qri use study

Conditions: Covid 19

Summary: the objective of the study is to determine the usability of the glowtest covid-19 antigen home test in a simulated home use environment. this is an open label study to evaluate the usability of the glowtest covid-19 antigen home test using information from the quick reference instructions and website.

the purpose of this study is to evaluate the usability of the glowtest covid-19 antigen home test in home use. the arion bio glowtest covid-19 antigen home test is a lateral flow immunoassay intended for the qualitative detection of sars-cov-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a covid-19 infection. the test is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older or adult collected anterior nares swab samples from individuals aged 2 to 13. the objective of the study is to determine the usability of the glowtest covid-19 antigen home test in a simulated home use environment. this is an open label study to evaluate the usability of the glowtest covid-19 antigen home test using information from the quick reference instructions and website. 30 subjects (including both english speaking and spanish speaking) will be split evenly into two sections: 15 participants testing themselves and 15 participants testing another person (child). there will be one testing site in the united states (us).

Eligibility criteria:
inclusion criteria: * an institutional review board (irb) approved informed consent/assent is signed and dated prior to any study-related activities. * males and females ages 2 and older. * subject is willing to provide a self-collected nasal swab sample. (if under the age of 14, the sample will be collected by an adult.) * subject agrees to complete all aspects of the study exclusion criteria: * subject has a visual impairment that cannot be restored with glasses or contact lenses. * subject has prior medical or laboratory training. * subject uses home diagnostics, e.g., glucose meters, hiv tests. * subject has prior experience with home covid test kits.

Keywords: virus
bone health observational study

Conditions: Prostate Cancer

Summary: prostate cancer patients treated with lhrh agonists (e.g., goserelin) lose bone mineral density (bmd). using a prospective, observational study design, we propose that monitoring how physicians manage cancer treatment induced bone loss(ctibl) in their patients. the gold standard for evaluating bmd is dual energy x-ray absorptiometry (dexa). the proposed study will provide some of the first prospective data on the rates of skeletal related events (sres) in prostate cancer patients undergoing adt and help develop official guidelines on the use of dexa screening for prostate cancer patients.

a consequence of adt is the gradual bone loss, so-called cancer treatment induced bone loss (ctibl). the current standard of care is the addition of vitamin d and calcium upon the initiation of adt. moreover, bisphosphonates are now being considered to treat and prevent ctibl. however, bisphosphonates are costly, thus there is a desire to identify or target a specific subset of patients who would most benefit from the treatment. by obtaining baseline bmd and monitoring for skeletal related events (sres), we hope to identify that specific sub-set of patients who would most benefit from the treatment. using a prospective, observational study design, we propose monitoring how physicians manage ctibl in their patients.

Eligibility criteria:
inclusion criteria: * patients willing to provide written informed consent. * patients for whom androgen deprivation therapy (adt) with zoladex® is indicated for at least 1 year. * patients started on zoladex® within the last 4 months. exclusion criteria: * patient had surgery or significant traumatic injury occurring within 1 month prior to consent. * known hypersensitivity to goserelin acetate or any of the components found in zoladex®. * any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.

Keywords: prostate cancer prostatic adenoma prostatic neoplasm
ciprofloxacin utilization and adverse events occurrence in community pharmacy setting

Conditions: Ciprofloxacin Adverse Reaction

Summary: background: ciprofloxacin is a fluoroquinolone that is commonly used to treat a variety of diseases. ciprofloxacin resistance is rising, resulting in suboptimal patient care. the goal of this study was to evaluate ciprofloxacin use in the community in terms of acceptable prescription, dose, frequency, and duration of use. methods: a cross-sectional research was done in egyptian community pharmacies by community pharmacists. patients who were administered oral ciprofloxacin during the research period were included.

from september 2021 to february 2022, a cross-sectional, research was undertaken to evaluate ciprofloxacin usage. the investigation was carried out by community pharmacists in seven egyptian community pharmacies. data collection: data gathered from pharmacy patients' records on a data collection form that included the factors indicated. the general symptoms questionnaire, physical examination, and blood testing were used to identify adverse occurrences. study variables: * age, gender, pregnancy/lactation * department/indication * dose, frequency, duration, adverse events, drug interactions. data was categorized and analyzed using appropriate software.

Eligibility criteria:
inclusion criteria: * all ciprofloxacin included prescription during the study period. exclusion criteria: * un included ciprofloxacin prescription.

Keywords: ciprofloxacin use evaluation drug interaction
effects of therapeutic exercise in patients with fibromyalgia

Conditions: Therapeutic Exercise; Chronic Pain

Summary: fibromyalgia syndrome is characterized by chronic generalized musculoskeletal pain associated with fatigue, sleep disturbances and some biochemical markers. the european league againts rheumatism (eular) described an algorithm how to treat step by step these patients. the objective of this trial is to evaluate if therapeutic exercise is effective on fatigue, pain threshold, quality of life, quality of sleep, pain coping and biochemical and genetic markers. for this purpose, the investigators conduct a randomized controlled trial double-blind (patient and examiner). the investigators included patients diagnosed of fibromyalgia according to the american college of rheumatology (acr). patients included one group receiving exercise therapy consisting of 3 treatment sessions a week over 10 weeks. the variables are measured at the beginning and end of treatment.


Eligibility criteria:
inclusion criteria: * diagnosed medically with fibromyalgia * diagnosed according to the american college of rheumatology criteria * agreement to attend to treatment sessions exclusion criteria: * any kind of contraindications for physical activity * other kind of diseases that could limit the intervention * previous surgery last year * medication modifications in the last 3 months
thymoves: screening and exercise to improve muscle, enhance quality of life, and reduce fall risk in thyroid disease

Conditions: Thyroid Disease; Hashimoto&#39;s Thyroiditis; Hyperthyreosis and Goiter; Hypothyroidism

Summary: objectives: this study aims to assess health-related quality of life (qol) in adults with thyroid hormone disorders and identify modifiable factors to improve qol in patients with hashimoto's thyroiditis (ht) and multinodular toxic goiter (mntg) through an exercise intervention. primary outcome: 1. assess the impact of a tailored exercise program on health-related qol in patients with ht and mntg using the thypro questionnaire. secondary outcomes: 1. evaluate the need for a screening tool to identify thyroid patients with reduced health-related qol despite being euthyroid. 2. assess the impact of the exercise intervention on body composition, strength, and balance function in ht and mntg patients. methods: the study is a combined cross-sectional survey and randomized controlled trial into the health related qol in patients diagnosed with thyroid hormone disease. the cross-sectional survey will assess the overall health-related qol in patients diagnosed with thyroid hormone disease, and help identify eligible participants for the subsequent rct. the rct will evaluate the efficacy of a comprehensive screening and exercise intervention in patients ≥ 65 years diagnosed with ht or mntg, experiencing reduced health-related qol. participants: the aim is to recruit 74 patients with ht and 74 patients with mntg, including 50 participants from each group with reduced health-related qol (defined in this study as thypro score ≥ 30) and 24 with good health-related qol (thypro score ≤ 20)


Eligibility criteria:
inclusion criteria: 1. women with minimum 65 years of age, with no upper limit. 2. verified diagnosis of ht or mntg 3. euthyroid for at least 6 months 4. signed the informed consent exclusion criteria: 1. current participation in a structured exercise program or regular physical exercise activity above 5 hours per week 2. previous experience with rhythm-based multitask exercise. 3. diagnosed with significant neurological diseases (e.g. multiple sclerosis and myasthenia gravis), vestibular diseases or newly orthopedic surgeries (e.g. knee or hip replacement) 4. fully dependent on walking aids 5. active malignancy or terminal illness 6. inability to understand danish written and/or verbally 7. having severely impaired cognitive function, defined as a score below 8 on the cognitive assessment "the short orientation-memory-concentration test" 8. treatment with amiodarone within the last year 9. no changes within the last six months in medications affecting weight or body composition - e.g., glp-1 electrolyte/fluid balance - e.g., diuretics or corticosteroid 10. participation in other clinical intervention studies within the last six months for the cross sectional survey: inclusion criteria: 1. men and women with a minimum of 18 years 2. diagnosis of primary hypothyroidism or primary hyperthyroidism

Keywords: health-related quality of life exercise intervention
early phase clinical trial about therapeutic biological product mix for treating cea positive rectal cancer

Conditions: Rectal Cancer

Summary: conducting an early phase clinical trial to assess cea antigen presentation therapeutic biological product mix activity that suggests the potential for clinical benefit of cea positive rectal cancer patients. 1. treat cea positive rectal cancer via trained immunity. 2. activate human cea protein antigen presentation reaction. 3. the human antigen presenting cells (apcs) can treat the cea protein antigen into small peptide fragments, and then kill cea positive rectal cancer cells in vivo.

* conducting an early phase clinical trial to assess cea antigen presentation therapeutic biological product mix activity that suggests the potential for clinical benefit of cea positive rectal cancer patients * 20 cea positive rectal cancer patients * positive testing cea by blood-drawing * tb negative participant is negative igra blood test with tb antigens * clinical rectal cancer diagnosis stage 0 - iia * clinical rectal cancer diagnosis without symptoms * clinical rectal cancer diagnosis without metastasis * cea protein antigen 0.05 mg plus bcg organism 50 mg mix * by the percutaneous route with the multiple puncture device * positive igra blood test with cea protein antigen after percutaneous use 21 days * our trial duration will be 12-week duration

Eligibility criteria:
conducting an early phase clinical trial to assess cea antigen presentation therapeutic biological product mix that suggests the potential for clinical benefit of cea positive rectal cancer patients. 20 cea positive rectal cancer patients inclusion criteria: * clinical rectal cancer diagnosis stage 0 - iia * clinical rectal cancer diagnosis without symptoms * clinical rectal cancer diagnosis without metastasis * positive testing cea by blood-drawing * tb negative participant is negative igra blood test with tb antigens. exclusion criteria: * pregnant * thrombosis * allergy * tb positive participant is positive igra blood test with tb antigens. * symptoms of rectal cancer * metastasis of rectal cancer * evidence of critical illness

Keywords: cea antigen presentation apc trained immunity innate immune memory rectal cancer
impact of rifaximin therapy on intestinal byproducts in end-stage renal disease

Conditions: End Stage Renal Disease

Summary: the purpose of this study is to determine if rifaximin reduces serum trimethylamine-n-oxide (tmao) levels in patients with end-stage renal disease.

study participants will undergo 3 study visits: baseline, day 7 (immediately post-therapy), day 21 (2 weeks post-therapy). all participants will provide blood and stool samples at each visit.

Eligibility criteria:
inclusion criteria: * diagnosis of end-stage renal disease * receiving chronic intermittent hemodialysis exclusion criteria: * patients with less advanced kidney disease * inability or unwillingness to provide informed consent * patients who may be pregnant * hemodynamically unstable patients * patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease * patients with ongoing or recent infection and those with history of c-diff infection * patients with abnormal bowel structure secondary to surgical or anatomic variations * patients on certain medications, including immunosuppressants, antidiarrheal agents, or recent (within the last 2 months) use of antibiotics
personalized antisense oligonucleotide therapy for a single participant with lmnb1 mutation associated autosomal dominant leukodystrophy (adld)

Conditions: Autosomal Dominant Leukodystrophy

Summary: this research project entails delivery of a personalized antisense oligonucleotide (aso) drug designed for a single participant with autosomal dominant leukodystrophy (adld) due to lmnb1 mutation

this is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (aso) treatment in a single participant with autosomal dominant leukodystrophy (adld) due to lmnb1 mutation

Eligibility criteria:
inclusion criteria: * informed consent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s). * autosomal dominant adult-onset leukodystrophy (adld) caused by an lmnb1 duplication mutation * ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records. * willingness to follow contraceptive guidance during the intervention period and for at least 40 weeks after the last dose of study intervention exclusion criteria: * participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures
dci covid-19 surveillance project

Conditions: Covid19

Summary: this is a prospective longitudinal census study conducted at a single center (dci inc., henry avenue, philadelphia). the purpose of this study is to gain information about covid-19 infection and antibody response in an in-center dialysis population. the investigators hypothesize that screening and surveillance for covid-19 positive test (viral infection) and antibodies response to infection (potential immunity) in a dialysis center population within a high-prevalence region can provide foundational information to guide approaches toward prevention of covid-19 related illness in a susceptible population. participants will be given a questionnaire initially and monthly over the study period to find out whether they have had covid-19 infection, hospitalization, or symptoms. a nasopharyngeal swab test for covid-19 infection and a blood sample for covid-19 antibody will be collected monthly for the study period.


Eligibility criteria:
inclusion criteria: * patients who receive in-center chronic dialysis (\>3 months) at dci henry avenue * patients who are able to consent for study exclusion criteria: * patients receiving transient hemodialysis at dci or receiving hemodialysis for acute renal failure * patients who are unable to consent * patients who are receiving other forms of dialysis therapy (e.g. home hemodialysis, peritoneal dialysis) * patients whose life expectancy is \<12 months * patients who are planning to leave the dialysis center within 12 months
menopausal treatment using relaxation exercises (mature)

Conditions: Hot Flushes; Hot Flashes

Summary: hot flashes occur in as many as two thirds of u.s. women during menopause and are severe enough to require treatment in 20%. although postmenopausal hormone therapy is effective in suppressing hot flashes, it is associated with increased risk for a variety of serious adverse effects. there is an urgent need for alternative treatments that are effective, safe, and easy to use. in this study, the investigators will compare two different types of behavioral relaxation therapies, paced respiration and music therapy, for treatment of menopausal hot flashes. effects on frequency of hot flashes, other symptom and quality-of-life outcomes associated with hot flashes, and physiologic measures of sympathetic/parasympathetic activity will be examined.


Eligibility criteria:
inclusion criteria 1. women aged 40 through 59 years at the time of screening. 2. perinenopausal or postmenopausal. 3. adequate adherence to study procedures during a 1-week run-in. 4. at least 4 hot flashes per 24 hours recorded by a hot flash monitor and diary. 5. capable of understanding study procedures and giving informed consent. 6. willing to refrain from using other treatments for hot flashes during the study period. exclusion criteria 1. pregnant or breastfeeding in the past year. 2. current or recent use of medications known to affect hot flashes. 3. resting blood pressure less than 100/60. 4. spontaneous resting breathing rate less than 10 breaths/minute. 5. chronic medical therapy for pulmonary disease. 6. known sensitivity to adhesives. 7. cardiac pacemaker or implanted defibrillator. 8. no access to a telephone. 9. plans to move out of the area or travel by airplane in ways that would interfere with the study. 10. inability to sign an informed consent, participate in interviews, or understand and complete questionnaires in english. 11. report conditions that, in the judgment of the investigators, render potential participants unlikely to follow the protocol. 12. participation in another research study involving investigational drugs or devices.
milady: a randomized, placebo-controlled safety and efficacy trial of ssr240600c in treatment of overactive bladder or urge urinary incontinence.

Conditions: Overactive Bladder

Summary: to evaluate the safety and efficacy of ssr240600c versus placebo on clinical and cystometric parameters in patients with oab and uui.

prospective, randomized, parallel group, double-dummy, placebo and active-controlled (detrol la - tolterodine) trial wherein patients with oab or uui will receive single daily does of either ssr240600c 500 mg, tolterodine 4 mg or placebo for four weeks. baseline and end of study cystometry will be performed; daily symptom diaries will be completed during the trial and health-related quality of life will be measured before and after study drug treatment. patients will be followed-up one week after completion of the trial. study participation will include 5 visits over a period of six weeks.

Eligibility criteria:
inclusion criteria: * females between 18 and 75 years, inclusive clinical diagnosis of oab/uui (symptoms of frequent micturition, urinary urgency) * bladder capacity \</= 300 ml by cystometry exclusion criteria: * history of interstitial cystitis, bladder outlet obstruction or other significant genitourinary disorder * current urinary tract infection * neurological bladder dysfunction * treatment with drugs that may interfere with cyp3a4 metabolic function * history of stress urinary incontinence

Keywords: cystometry nk1 antagonist ssr240600c
prospective, longitudinal multicentric survey in the therapeutic care of mild to moderate ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the primary objective of this study is to confirm the long-term efficacy (remission and maintenance in remission) of current validated treatments. each patient will be followed during 3 years in this non-interventional trial.


Eligibility criteria:
inclusion criteria: * 18 years old or above * ulcerative colitis, whatever the extension, in mild to moderate flare-up (including proctitis) * having received the information sheet exclusion criteria: * participating, at the time of inclusion, in another study using an investigational drug or device
partners for life: off-line health promotion program for ultra-orthodox jewish women during the covid-19 pandemic

Conditions: Health Behavior

Summary: the purpose of this study is to evaluate a unique culturally-tailored intervention aimed at increasing healthy eating and physical activity in ultra-orthodox jewish women during the covid-19 pandemic. utilizing a pre-post study design, this intervention is based on the cdc's diabetes prevention program (dpp) and integrates low-tech media, partner learning, group support, and practical workbook content.

uoj women in israel have poorer health outcomes and sub-optimal health behaviors than their counterparts. contributing factors to these disparities include poverty, limited access to information, and insufficient culturally-appropriate opportunities. covid-19 has exacerbated this inequity, with reduced income, opportunities and time availability, as well as increased weight, social isolation, loss, stress and emotional issues. while covid-19 brought these health issues to the forefront, they are ongoing - and currently overlooked. the purpose of this study is to evaluate a unique culturally-tailored intervention aimed at increasing healthy eating and physical activity in ultra-orthodox jewish women during the covid-19 pandemic. utilizing a pre-post study design, this intervention is based on the cdc's diabetes prevention program (dpp) and integrates low-tech media, partner learning, group support, and practical workbook content. participants are recruited through an ultra-orthodox jewish continuing education institution for women and either register with a friend or are assigned a partner. each woman receives a pedometer and workbook with information and skill-building worksheets to complete weekly in pairs (via phone or in person). all dyads will join weekly phone-based group meetings led by a group leader, to share challenges and successes as well as problem solve. it is hypothesized that this intervention will increase the targeted health behaviors as well as reduce weight in participants.

Eligibility criteria:
inclusion criteria: females aged 18-85, willingness to commit to participation in the lifestyle intervention and follow-up. - exclusion criteria: pregnancy, history of schizophrenia, severe depression, untreated bipolar disorder, end-stage renal disease, type 1 diabetes, unstable angina, congestive heart failure, inability to participate in the group without assistance, dementia, inability to communicate in hebrew.